Sun Pharma specialty drug Tildrakizumab makes it to China’s reimbursement list

Share this post on:

Sun Pharma on Wednesday said its top-selling specialty medication Tildrakizumab used against psoriasis has been included in category B of China’s National Reimbursement Drug List (NRDL), which shall be officially implemented from January 1, 2024.

The inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs fully or partially reimbursed by the national basic health insurance in China covering 96% of the population or more than 1.36 billion people. Sun Pharma will become eligible to receive sales milestone payments, and royalties on net sales, from its licensing partner.

The drug was approved by China’s drug regulator – the National Medical Products Administration (NMPA) in May this year. The Mumbai-based drug maker in 2019 has out-licensed tildrakizumab to a subsidiary of China Medical System Holdings Limited (CMS) for development, regulatory filings and commercialisation of the product in Greater China.

Tildrakizumab enjoys patent protection in China.

China has more than 6.5 million people currently suffering from psoriasis and psoriatic arthritis. Tildrakizumab injection sold under brand name ILUMETRI in China is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

“The inclusion of ILUMETRI in category B of the National Reimbursement Drug List will further improve the accessibility and affordability of the innovative drug to benefit more patients,” the company said in a statement.Shares of Sun Pharma rose 1.24% to close at Rs 1232.75 on BSE, the benchmark Sensex increased 0.05% to end at 69,584.60 points.

Share this post on:

Leave a Reply

Your email address will not be published. Required fields are marked *